This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (21)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Multiple Sclerosis/ Demyelinating Disease  • Immunologic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Bernd C. Kieseier, MD; Juan J. Archelos, MD; Hans-Peter Hartung, MD

Arch Neurol. 2004;61:929-932.

Background  Interferon beta and statins are known to exert immunomodulatory actions by inhibiting gene transcription and translation of various proinflammatory molecules. Although interferon beta represents a mainstay in therapy for multiple sclerosis (MS), statins are considered a potential new approach in treating MS.

Objective  To investigate the effect of interferon beta and statins on the posttranslational activity of matrix metalloproteinases (MMPs) released from mononuclear cells in vitro that were obtained from patients with MS and healthy donors.

Design  Blood samples from 10 patients with a relapsing-remitting course of MS and 5 matched healthy individuals were studied. Peripheral blood mononuclear cells were isolated and stimulated with an antibody to CD3, phytohemagglutinin, or medium alone as a negative control. Proteolytic activity was investigated in the supernatants by means of sodium dodecyl sulfate–polyacrylamide gel electrophoresis zymography in which gels were incubated with interferon beta or simvastatin during development. Zones of gelatin digestion were visualized and quantified.

Results  Incubation with interferon beta resulted in an inhibition of the gelatinolytic activity of MMP-9 and MMP-2. In contrast, simvastatin enhanced the proteolytic capacity of MMP-2 and MMP-9, with a statistically significant increase of MMP-2 activity when compared with findings in controls. There were no differences in the enzymatic response between patients with MS and healthy individuals.

Conclusions  Interferon beta exhibits inhibitory effects at the posttranslational level of MMP activity, whereas simvastatin augments the proteolytic activity of MMP-2 and MMP-9, suggesting that statins exert anti-inflammatory and proinflammatory effects. This dual mechanism of action should be considered, given the recent interest in developing these drugs for treatment of MS.

From the Departments of Neurology, Heinrich-Heine-University, Düsseldorf, Germany (Drs Kieseier and Hartung), and Karl-Franzens University, Graz, Austria (Dr Archelos).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Emerging Therapies for Relapsing Multiple Sclerosis
Cohen
Arch Neurol 2009;66:821-828.
ABSTRACT | FULL TEXT  

Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis
Montecucco and Mach
Rheumatology (Oxford) 2009;48:11-22.
ABSTRACT | FULL TEXT  

Statins to treat multiple sclerosis: Friend or foe?
Goldman and Cohen
Neurology 2008;71:1386-1387.
FULL TEXT  

Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis
Birnbaum et al.
Neurology 2008;71:1390-1395.
ABSTRACT | FULL TEXT  

Simvastatin Inhibits IL-17 Secretion by Targeting Multiple IL-17-Regulatory Cytokines and by Inhibiting the Expression of IL-17 Transcription Factor RORC in CD4+ Lymphocytes
Zhang et al.
J. Immunol. 2008;180:6988-6996.
ABSTRACT | FULL TEXT  

Atorvastatin Does Not Alter Interferon Beta-Induced Changes of Serum Matrix Metalloproteinase 9 and Tissue Inhibitor of Metalloproteinase 1 in Patients With Multiple Sclerosis
Sellner et al.
Arch Neurol 2008;65:672-674.
FULL TEXT  

Combination Therapy With Interferon Beta-1a and Doxycycline in Multiple Sclerosis: An Open-Label Trial
Minagar et al.
Arch Neurol 2008;65:199-204.
ABSTRACT | FULL TEXT